Philip M. Wallace

Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule

Peter S. Linsley, Philip M. Wallace, Jennifer Johnson et al. · Science · 1992 · 805 citations

Autoimmune Disease, Allergy, Soluble Form +14

New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Philip E. Thorpe, Philip M. Wallace, Phillip P. Knowles et al. · PubMed · 1987 · 204 citations

Immunotoxicology, Disulfide Linkage, Improved Stability +20

Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

P E Thorpe, Philip M. Wallace, P.P. Knowles et al. · PubMed · 1988 · 156 citations

Deglycosylated Ricin A-chain, Smpt Cross-linker, Immunotoxicology +18

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.

Maria‐Ana Ghetie, Richard May, Mark Till et al. · PubMed · 1988 · 118 citations

Immunology, Immunoediting, Pathology +22

CTLA4Ig TREATMENT AMELIORATES THE LETHALITY OF MURINE GRAFT-VERSUS-HOST DISEASE ACROSS MAJOR HISTOCOMPATIBILITY COMPLEX BARRIERS

Philip M. Wallace, Jennifer Johnson, John F. MacMaster et al. · Transplantation · 1994 · 117 citations

Histocompatibility, Transplant Rejection, Cell Therapy +15